234 related articles for article (PubMed ID: 27453746)
1. Outcome of urinary bladder cancer after combined therapies.
Anghel RM; Gales LN; Trifanescu OG
J Med Life; 2016; 9(2):153-9. PubMed ID: 27453746
[TBL] [Abstract][Full Text] [Related]
2. Outcome of urinary bladder cancer after combined therapies.
Anghel RM; Gales LN; Trifanescu OG
J Med Life; 2016; 9(1):95-100. PubMed ID: 27974922
[No Abstract] [Full Text] [Related]
3. Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy.
Chen J; Miranda G; Cai J; Daneshmand S; Djaladat H
Scand J Urol; 2019; 53(2-3):123-128. PubMed ID: 31081431
[No Abstract] [Full Text] [Related]
4. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
6. Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy.
Amini E; Ahmadi N; Clifford TG; Hugen CM; Bazargani ST; Cai J; Miranda G; Sherrod AE; Daneshmand S; Djaladat H
Int Urol Nephrol; 2019 Mar; 51(3):435-441. PubMed ID: 30706249
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
Pouessel D; Bastuji-Garin S; Houédé N; Vordos D; Loriot Y; Chevreau C; Sevin E; Beuzeboc P; Taille A; Le Thuaut A; Allory Y; Culine S
Clin Genitourin Cancer; 2017 Feb; 15(1):e45-e52. PubMed ID: 27554584
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
9. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
Weight CJ; Garcia JA; Hansel DE; Fergany AF; Campbell SC; Gong MC; Jones JS; Klein EA; Dreicer R; Stephenson AJ
Cancer; 2009 Feb; 115(4):792-9. PubMed ID: 19127557
[TBL] [Abstract][Full Text] [Related]
10. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
[TBL] [Abstract][Full Text] [Related]
11. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy.
Masson-Lecomte A; Xylinas E; Bouquot M; Sibony M; Allory Y; Comperat E; Zerbib M; de la Taille A; Rouprêt M
World J Urol; 2015 Aug; 33(8):1087-93. PubMed ID: 25179011
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
13. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience.
Dorff TB; Tsao-Wei D; Miranda G; Skinner DG; Stein JP; Quinn DI
World J Urol; 2009 Feb; 27(1):39-44. PubMed ID: 19020886
[TBL] [Abstract][Full Text] [Related]
16. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
Gamal El-Deen HS
J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
[TBL] [Abstract][Full Text] [Related]
17. [Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
Asadauskiene J; Aleknavicius E; Zelviene TP; Jankevicius F
Medicina (Kaunas); 2006; 42(10):781-7. PubMed ID: 17090976
[TBL] [Abstract][Full Text] [Related]
18. Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer.
Cobo M; Delgado R; Gil S; Herruzo I; Baena V; Carabante F; Moreno P; Ruiz JL; Bretón JJ; Del Rosal JM; Fuentes C; Moreno P; García E; Villar E; Contreras J; Alés I; Benavides M
Clin Transl Oncol; 2006 Dec; 8(12):903-11. PubMed ID: 17169764
[TBL] [Abstract][Full Text] [Related]
19. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
